Patents by Inventor Hirotaka Kurebayashi
Hirotaka Kurebayashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230250116Abstract: A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.Type: ApplicationFiled: November 10, 2022Publication date: August 10, 2023Inventors: Adam Siddiqui-Jain, Paul Flynn, Yuji Fujiwara, Shuji Masumoto, Hiroaki Tanaka, Hirotaka Kurebayashi, Takahiko Hashizuka, Yuka Arikawa
-
Patent number: 11530231Abstract: A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.Type: GrantFiled: April 8, 2021Date of Patent: December 20, 2022Assignee: Sumitomo Pharma Oncology, Inc.Inventors: Adam Siddiqui-Jain, Paul Flynn, Shuji Masumoto, Hiroaki Tanaka, Hirotaka Kurebayashi, Takahiko Hashizuka, Yuka Arikawa
-
Publication number: 20220267282Abstract: The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.Type: ApplicationFiled: March 2, 2022Publication date: August 25, 2022Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Seiji HORI, Futoshi HASEGAWA, Daisuke URABE, Hirotaka KUREBAYASHI
-
Patent number: 11299465Abstract: The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.Type: GrantFiled: January 7, 2020Date of Patent: April 12, 2022Assignee: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Seiji Hori, Futoshi Hasegawa, Daisuke Urabe, Hirotaka Kurebayashi
-
Publication number: 20210332071Abstract: A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.Type: ApplicationFiled: April 8, 2021Publication date: October 28, 2021Inventors: Adam Siddiqui-Jain, Paul Flynn, Yuji Fujiwara, Shuji Masumoto, Hiroaki Tanaka, Hirotaka Kurebayashi, Takahiko Hashizuka, Yuka Arikawa
-
Patent number: 11034710Abstract: A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.Type: GrantFiled: December 4, 2019Date of Patent: June 15, 2021Assignee: Sumitomo Dainippon Pharma Oncology, Inc.Inventors: Adam Siddiqui-Jain, Paul Flynn, Yuji Fujiwara, Shuji Masumoto, Hiroaki Tanaka, Hirotaka Kurebayashi, Takahiko Hashizuka, Yuka Arikawa
-
Publication number: 20200317623Abstract: The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.Type: ApplicationFiled: January 7, 2020Publication date: October 8, 2020Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Seiji HORI, Futoshi HASEGAWA, Daisuke URABE, Hirotaka KUREBAYASHI
-
Publication number: 20200255462Abstract: A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.Type: ApplicationFiled: December 4, 2019Publication date: August 13, 2020Inventors: Adam SIDDIQUI-JAIN, Paul FLYNN, Yuji FUJIWARA, Shuji MASUMOTO, Hiroaki TANAKA, Hirotaka KUREBAYASHI, Takahiko HASHIZUKA, Yuka ARIKAWA
-
Patent number: 10562861Abstract: The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.Type: GrantFiled: October 23, 2018Date of Patent: February 18, 2020Assignee: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Seiji Hori, Futoshi Hasegawa, Daisuke Urabe, Hirotaka Kurebayashi
-
Publication number: 20190119220Abstract: The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.Type: ApplicationFiled: October 23, 2018Publication date: April 25, 2019Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Seiji Hori, Futoshi Hasegawa, Daisuke Urabe, Hirotaka Kurebayashi
-
Patent number: 10150743Abstract: The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.Type: GrantFiled: May 11, 2016Date of Patent: December 11, 2018Assignee: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Seiji Hori, Futoshi Hasegawa, Daisuke Urabe, Hirotaka Kurebayashi
-
Publication number: 20160251319Abstract: The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.Type: ApplicationFiled: May 11, 2016Publication date: September 1, 2016Applicants: Sumitomo Dainippon Pharma Co., Ltd., Astrazeneca AktiebolagInventors: Seiji HORI, Futoshi HASEGAWA, Daisuke URABE, Hirotaka KUREBAYASHI
-
Patent number: 9376398Abstract: The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.Type: GrantFiled: May 17, 2013Date of Patent: June 28, 2016Assignees: Sumitomo Dainippon Pharma Co., LTD, Astrazeneca AktiebolagInventors: Seiji Hori, Futoshi Hasegawa, Daisuke Urabe, Hirotaka Kurebayashi
-
Publication number: 20150099770Abstract: The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.Type: ApplicationFiled: May 17, 2013Publication date: April 9, 2015Inventors: Seiji Hori, Futoshi Hasegawa, Daisuke Urabe, Hirotaka Kurebayashi
-
Publication number: 20110136801Abstract: The present invention provides compounds of formula (I): wherein Ra, Rb, Rc, R1, R2, R3, X1, Y1, Z1, A, n and m are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.Type: ApplicationFiled: December 2, 2010Publication date: June 9, 2011Applicants: Dainippon Sumitomo Pharma Co. Ltd., AstraZeneca ABInventors: Yoshiaki Isobe, Mai Kasai, Tomoaki Nakamura, Shingo Tojo, Hirotaka Kurebayashi